Molecular Oncology Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), 28040, Madrid, Spain.
Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, Spain.
Sci Rep. 2018 Aug 29;8(1):13038. doi: 10.1038/s41598-018-31326-4.
Although Ras genes are frequently mutated in human tumors, these mutations are uncommon in breast cancer. However, many breast tumors show evidences of Ras pathway activation. In this manuscript, we have analyzed and characterized mouse mammary tumors generated by random Sleeping Beauty transposon mutagenesis and identify ERAS -a member of the RAS family silenced in adult tissues- as a new gene involved in progression and malignancy of breast cancer. Forced expression of ERAS in human non-transformed mammary gland cells induces a process of epithelial-to-mesenchymal transition and an increase in stem cells markers; these changes are mediated by miR-200c downregulation. ERAS expression in human tumorigenic mammary cells leads to the generation of larger and less differentiated tumors in xenotransplant experiments. Immunohistochemical, RT-qPCR and bioinformatics analysis of human samples show that ERAS is aberrantly expressed in 8-10% of breast tumors and this expression is associated with distant metastasis and reduced metastasis-free survival. In summary, our results reveal that inappropriate activation of ERAS may be important in the development of a subset of breast tumors. These findings open the possibility of new specific treatments for this subset of ERAS-expressing tumors.
虽然 Ras 基因在人类肿瘤中经常发生突变,但在乳腺癌中却很少见。然而,许多乳腺癌肿瘤表现出 Ras 途径激活的证据。在本手稿中,我们分析并描述了由随机 Sleeping Beauty 转座子诱变产生的小鼠乳腺肿瘤,并鉴定出 ERAS-一种在成人组织中沉默的 Ras 家族成员-是参与乳腺癌进展和恶性的新基因。在人非转化乳腺细胞中强制表达 ERAS 会诱导上皮-间充质转化过程和干细胞标志物增加;这些变化是由 miR-200c 的下调介导的。在人致瘤性乳腺细胞中表达 ERAS 会导致异种移植实验中产生更大和分化程度更低的肿瘤。对人样本的免疫组织化学、RT-qPCR 和生物信息学分析表明,ERAS 在 8-10%的乳腺癌中异常表达,这种表达与远处转移和降低无转移生存相关。总之,我们的结果表明,ERAS 的不适当激活可能在一部分乳腺癌的发展中很重要。这些发现为这部分表达 ERAS 的肿瘤提供了新的特异性治疗方法的可能性。